Results of a Phase II Open-Label Trial of Bortezomib in Patients with Multiple Myeloma Who Have Undergone High-Dose Melphalan Therapy Followed by Autologous Peripheral Blood Stem Cell Transplantation and Failed to Achieve a Complete Response.

被引：0
|
作者：
Rifkin, Robert M. [1 ,2 ]
Spitzer, Gary [1 ,3 ]
Greenspan, Andrew [1 ,4 ]
Schwerkoske, John F. [1 ,5 ]
Mandanas, Romeo A. [6 ]
Stephenson, Joe [1 ,3 ]
Kannarkat, George T. [1 ,7 ]
Zhan, Feng [1 ]
Asmar, Lina [1 ]
Beveridge, Roy [1 ,7 ]
机构：
[1] US Oncol Res Inc, Houston, TX USA
[2] Rocky Mt Canc Ctr, Denver, CO USA
[3] Canc Ctr Carolinas, Greenville, SC USA
[4] Cent Indiana Canc Ctr, Indianapolis, IN USA
[5] Minnesota Oncol Hematol, St Paul, MN USA
[6] Canc Care Associates W, Oklahoma City, OK USA
[7] Fairfax No Virginia Hematol Oncol, Fairfax, VA USA
来源：
BLOOD | 2008年 / 112卷 / 11期
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页码：960 / 960
页数：1
相关论文
共 50 条
  • [1] A phase II open-label trial of bortezomib in patients with multiple myeloma who have undergone an autologous peripheral blood stem cell transplant and failed to achieve a complete response
    Robert M. Rifkin
    Andrew Greenspan
    John F. Schwerkoske
    Romeo A. Mandanas
    Joe J. Stephenson
    George T. Kannarkat
    Feng Zhan
    Kristi A. Boehm
    Lina Asmar
    Roy Beveridge
    Investigational New Drugs, 2012, 30 : 714 - 722
  • [2] A phase II open-label trial of bortezomib in patients with multiple myeloma who have undergone an autologous peripheral blood stem cell transplant and failed to achieve a complete response
    Rifkin, Robert M.
    Greenspan, Andrew
    Schwerkoske, John F.
    Mandanas, Romeo A.
    Stephenson, Joe J.
    Kannarkat, George T.
    Zhan, Feng
    Boehm, Kristi A.
    Asmar, Lina
    Beveridge, Roy
    INVESTIGATIONAL NEW DRUGS, 2012, 30 (02) : 714 - 722
  • [3] Interim analysis of a phase II trial of bortezomib in patients with multiple myeloma who failed to achieve a complete response to autologous peripheral blood stem cell transplantation.
    Rifkin, RM
    Beveridge, RA
    Brunvand, MW
    Spitzer, G
    Kristi, BA
    Rauch, MA
    Zhan, F
    Asmar, L
    BLOOD, 2005, 106 (11) : 377B - 378B
  • [4] Combination of high-dose melphalan and bortezomib as conditioning regimen for autologous peripheral blood stem cell transplantation in multiple myeloma
    Miyamoto, Toshihiro
    Yoshimoto, Goichi
    Kamimura, Tomohiko
    Muta, Tsuyoshi
    Takashima, Shuichiro
    Ito, Yoshikiyo
    Shiratsuchi, Motoaki
    Choi, Ilseung
    Kato, Koji
    Takenaka, Katsuto
    Iwasaki, Hiromi
    Takamatsu, Yasushi
    Teshima, Takanori
    Akashi, Koichi
    INTERNATIONAL JOURNAL OF HEMATOLOGY, 2013, 98 (03) : 337 - 345
  • [5] Combination of high-dose melphalan and bortezomib as conditioning regimen for autologous peripheral blood stem cell transplantation in multiple myeloma
    Toshihiro Miyamoto
    Goichi Yoshimoto
    Tomohiko Kamimura
    Tsuyoshi Muta
    Shuichiro Takashima
    Yoshikiyo Ito
    Motoaki Shiratsuchi
    Ilseung Choi
    Koji Kato
    Katsuto Takenaka
    Hiromi Iwasaki
    Yasushi Takamatsu
    Takanori Teshima
    Koichi Akashi
    International Journal of Hematology, 2013, 98 : 337 - 345
  • [6] The efficacy of high-dose melphalan with autologous peripheral blood stem cell transplantation in patients with multiple myeloma
    Lee, JL
    Kim, SB
    Lee, GW
    Ryu, MH
    Kim, E
    Kim, S
    Kim, WK
    Lee, JS
    Kim, SH
    Suh, C
    YONSEI MEDICAL JOURNAL, 2003, 44 (05) : 800 - 810
  • [7] A Phase I/II Study of Escalating Doses of Bortezomib in Conjunction with High-Dose Melphalan as a Conditioning Regimen for Salvage Autologous Peripheral Blood Stem Cell Transplantation in Patients with Multiple Myeloma
    Biran, Noa
    Rowley, Scott D.
    Vesole, David H.
    Zhang, Shijia
    Donato, Michele L.
    Richter, Joshua
    Skarbnik, Alan P.
    Pecora, Andrew
    Siegel, David S.
    BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION, 2016, 22 (12) : 2165 - 2171
  • [8] High-dose therapy followed by autologous peripheral blood stem cell transplantation in myeloma associated neuropathy
    Kilidireas, C
    Papadimitriou, C
    Karandreas, N
    Politi, A
    Dimopoulos, M
    JOURNAL OF NEUROLOGY, 2005, 252 : 135 - 135
  • [9] Phase I/II Trial of Lenalidomide and High-Dose Melphalan with Autologous Stem Cell Transplantation for Relapsed Myeloma: Updated Results
    Shah, Nina
    Thall, Peter F.
    Milton, Denai R.
    Bashir, Qaiser
    Parmar, Simrit
    Lin, Pei
    Kebriaei, Partow
    Nieto, Yago
    Popat, Uday R.
    Hosing, Chitra
    Cornelison, Amanda
    Delgado, Ruby
    Shpall, Elizabeth J.
    Orlowski, Robert Z.
    Champlin, Richard E.
    Qazilbash, Muzaffar
    BLOOD, 2016, 128 (22)
  • [10] A Phase I Study of Bortezomib During Maintenance Phase After High-Dose Melphalan and Autologous Stem Cell Transplantation In Patients with Multiple Myeloma
    Abidi, Muneer H.
    Gul, Zartash
    Lum, Lawrence G.
    Abrams, Judith
    Cronin, Simon
    Ventimiglia, Marie
    Deol, Abhinav
    Ayash, Lois
    Al-Kachimi, Zaid
    Ratanatharathorn, Voravit
    Uberti, Joseph P.
    BLOOD, 2010, 116 (21) : 989 - 989
12345